STOCK TITAN

OSR Health WTS (OSRHW) Stock Price, News & Analysis

OSRHW OTC
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
90 180 sessions, November 5, 2025 to November 5, 2026
Largest daily move
+472.7% close of October 30, 2026

Company Description

OSR Holdings, Inc. (warrants trading under the symbol OSRHW on The Nasdaq Stock Market LLC) is a healthcare-focused company. According to available information, OSR Holdings is dedicated to healthcare outcomes and improving the quality of life for people and their families. The company’s activities include building and developing therapies and healthcare-related solutions.

Based on prior descriptions, OSR Holdings’ business includes developing oral immunotherapies for the treatment of cancer, working on design-augmented biologics for age-related and other degenerative diseases, and engaging in neurovascular intervention medical device and systems distribution in Korea. These areas indicate a focus on therapeutic development and medical technologies within the healthcare sector.

OSR Holdings, Inc. has securities registered under the U.S. Securities Exchange Act, with its common stock trading under the symbol OSRH on The Nasdaq Stock Market LLC and its redeemable warrants trading under OSRHW on the same exchange. The company is identified as an emerging growth company in its SEC filings. OSR Holdings, Inc. lists Bellevue, Washington as the location of its principal offices.

The warrants represented by the OSRHW symbol are described in SEC filings as redeemable warrants that are exercisable for shares of OSR Holdings’ common stock at a specified exercise price. These warrants are a separate class of securities from the common stock and are also listed on The Nasdaq Stock Market LLC.

Business focus and activities

According to previously published descriptions, OSR Holdings’ business activities span several healthcare-related areas:

  • Developing oral immunotherapies intended for cancer treatment.
  • Developing design-augmented biologics aimed at age-related and other degenerative diseases.
  • Distributing neurovascular intervention medical devices and systems in Korea.

These activities place the company within the broader healthcare and medical technology landscape, with an emphasis on therapeutic development and specialized medical devices.

Public company and governance context

OSR Holdings, Inc. files periodic and current reports with the U.S. Securities and Exchange Commission. In a Form 8-K, the company reported holding an annual meeting of stockholders, at which stockholders voted on the election of directors and several proposals, including an executive compensation proposal, an equity plan proposal, and a Nasdaq 20% issuance proposal. The filing indicates that a quorum of shares was present and that multiple director nominees were elected to serve until a future annual meeting of stockholders or until their successors are duly elected and qualified.

The same filing shows that stockholders approved proposals related to executive compensation, an equity plan, and a Nasdaq 20% issuance. These matters reflect typical governance and capital-related topics for a publicly traded emerging growth company.

OSRHW: Redeemable warrants

The OSRHW symbol specifically represents redeemable warrants of OSR Holdings, Inc. As described in SEC filings, these warrants are exercisable for shares of common stock of OSR Holdings at an exercise price stated in the filing. The warrants are listed on The Nasdaq Stock Market LLC as a separate security from the common stock (OSRH). Investors and market participants may follow OSRHW to understand trading in these warrants alongside the underlying common stock.

Regulatory and listing information

In its SEC filings, OSR Holdings, Inc. identifies its common stock and redeemable warrants as being registered under Section 12(b) of the Securities Exchange Act and listed on The Nasdaq Stock Market LLC. The company also indicates that it qualifies as an emerging growth company under applicable SEC rules. This status can affect certain reporting and disclosure requirements, as reflected in the company’s filings.

Sector classification

OSR Holdings, Inc. is associated with the Surgical & Medical Instruments & Apparatus sector classification. The company’s described activities in oral immunotherapies, biologics, and neurovascular intervention medical device and systems distribution align it with healthcare and medical technologies.

Key points for OSRHW-focused investors

For users interested in OSRHW, it is important to note that:

  • OSRHW represents redeemable warrants of OSR Holdings, Inc., not the common stock itself.
  • The warrants are exercisable for shares of OSR Holdings’ common stock at an exercise price specified in SEC filings.
  • Both the common stock (OSRH) and the warrants (OSRHW) are listed on The Nasdaq Stock Market LLC.
  • Corporate actions, governance decisions, and capital-related proposals disclosed in OSR Holdings’ SEC filings can affect both the common stock and the warrants.

Stock Performance

$0.0126
+5.88%
+0.0007
Last updated: November 5, 2026 at 16:00
+472.7%
Performance 1 week

OSR Health WTS (OSRHW) closed at $0.0126 on November 5, 2026. Over the past week, the price has gained 472.7%.

See what a $1,000 investment in OSRHW would be worth today

Average down calculator for OSRHW

OSRHW Metrics & Rankings

Month to date
+0.0%
View ranking

Price returns through November 5, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

No recent news available for OSRHW.

Financial Highlights

OSR Health WTS generated $2.9M in revenue in FY2025, retaining a 20.4% gross margin, operating income reached -$18.3M, and net income was -$18.0M. Diluted earnings per share stood at -$0.80. The company generated -$4.3M in operating cash flow. The current ratio was 0.16, measuring current assets divided by current liabilities.

$2.9M
Revenue (FY2025)
-$18.0M
Net Income (FY2025)
-$4.3M
Operating Cash Flow

Upcoming Events

No upcoming events scheduled for OSRHW.

Short Interest History

Last 12 Months

Short interest in OSR Health WTS (OSRHW) currently stands at 900 shares, down 1.5% from the previous reporting period. Since November 2025, short interest has decreased by 95.8%.

Days to Cover History

Last 12 Months

Days to cover for OSR Health WTS (OSRHW) currently stands at 81.8 days, up 7338.2% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 8082%. Across the settlements charted above, it has ranged from 1.0 to 81.8 days.

OSRHW Company Profile & Sector Positioning

OSR Health WTS (OSRHW) and is listed on the OTC.

Investors comparing OSRHW often look at related companies in the same sector, including Evolution Global Acquisition Corp Units (EVOXU), Stellar V Capital Corp. (SVCC), Fortrea Holdings Inc. (FTRE), Columbia Seligman Premium Technology Growth Fund, Inc. (STK), and Aldel Financial II Inc. (ALDF). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate OSRHW's relative position within its industry.

Frequently Asked Questions

The current stock price of OSR Health WTS (OSRHW) is $0.0126 as of November 5, 2026.

The FY2025 revenue of OSR Health WTS (OSRHW) is $2.9M, from its most recent completed fiscal year.

The FY2025 net income of OSR Health WTS (OSRHW) is -$18.0M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of OSR Health WTS (OSRHW) is -$0.80 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of OSR Health WTS (OSRHW) is -$4.3M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The gross profit margin of OSR Health WTS (OSRHW) is 20.4% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of OSR Health WTS (OSRHW), current assets divided by current liabilities, was 0.16 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of OSR Health WTS (OSRHW) is $593K for FY2025, its most recent completed fiscal year.

The operating income of OSR Health WTS (OSRHW) is -$18.3M for FY2025, its most recent completed fiscal year. Learn about operating income.

OSR Holdings, Inc. is a healthcare company that, according to available descriptions, focuses on healthcare outcomes and improving the quality of life for people and their families. Its business includes developing oral immunotherapies, design-augmented biologics, and distributing neurovascular intervention medical devices and systems in Korea.

The OSRHW ticker represents redeemable warrants of OSR Holdings, Inc. As disclosed in SEC filings, these warrants are exercisable for shares of the company’s common stock at a specified exercise price and are listed on The Nasdaq Stock Market LLC.

According to an SEC Form 8-K, OSR Holdings, Inc.’s common stock, par value $0.0001 per share, trades under the symbol OSRH on The Nasdaq Stock Market LLC, and its redeemable warrants trade under the symbol OSRHW on the same exchange.

OSR Holdings, Inc. is associated with the Surgical & Medical Instruments & Apparatus sector, reflecting its focus on healthcare-related therapies and medical technologies, including neurovascular intervention medical device and systems distribution.

Based on prior descriptions, OSR Holdings, Inc. works on developing oral immunotherapies for the treatment of cancer and design-augmented biologics for age-related and other degenerative diseases.

According to earlier company descriptions, OSR Holdings, Inc.’s business includes neurovascular intervention medical device and systems distribution in Korea.

Yes. In its SEC Form 8-K, OSR Holdings, Inc. indicates by check mark that it is an emerging growth company as defined in SEC rules.

In a Form 8-K, OSR Holdings, Inc. reported that stockholders voted at an annual meeting on the election of director nominees, an executive compensation proposal, an equity plan proposal, and a Nasdaq 20% issuance proposal. Several director nominees were elected, and the proposals described in the filing were approved.